Preliminary investigation of a new serum marker for ovarian cancer

Simple item page
dc.contributor.authorBotha, Matthys H.en_ZA
dc.contributor.authorVeenstra, Hanneen_ZA
dc.contributor.authorVan der Merwe, Wilhelm K.en_ZA
dc.contributor.authorLaeng, R. Huberten_ZA
dc.contributor.authorNevin, Jamesen_ZA
dc.contributor.authorVan Wijk, Leonen_ZA
dc.contributor.authorSoeters, R.en_ZA
dc.contributor.authorBird, Sueen_ZA
dc.contributor.authorVan Helden, Paul D.en_ZA
dc.date.accessioned2013-07-03T08:19:10Z
dc.date.available2013-07-03T08:19:10Z
dc.date.issued2012
dc.descriptionCITATION: Botha, M. H. et al. 2012. Preliminary investigation of a new serum marker for ovarian cancer. South African Journal of Gynaecological Oncology, 4(1):13-20.
dc.descriptionThe original publication is available from: http://www.sajgo.co.za
dc.description.abstractObjectives: The long-term survival rate of patients with carcinoma of the ovary is poor, because this condition is usually diagnosed at an advanced stage of the disease. A reliable diagnostic and screening test is still lacking. Therefore, a serological test for a novel ovarian tumour antigen was developed and investigated in a clinical setting. This report describes this investigation, the aim of which was to provide data to decide whether the test warrants a further, large-scale trial. Methods: Serum collected from 25 patients with ovarian carcinoma, 24 healthy controls and 25 control patients with non-carcinomatous ovarian disorders was tested. The test utilises a monoclonal antibody, designated SMO47, to capture the tumour antigen and a normal form of the antigen from serum. Only the tumour antigen is detected by biotinylated Maakia amurensis lectin, which binds specifically to the sialic acid on the tumour antigen. Results: The sensitivity for the carcinoma patient group was 60% and the specificity for the control patient group was 76% when a cut-off value for 100% specificity in the healthy controls was used. The area under the receiver-operator characteristic curve was 0. 8200. CA125 tests were done on all serum, and the results compared graphically. The tumour antigen in the serum was very stable and did not seem to be affected by freezing or long storage at 4°C. Conclusions: The results of this first application of the new test are encouraging and warrant further investigation and testing of larger numbers of subjects to obtain more significant values for the sensitivity and specificity.
dc.description.urihttp://www.sajgo.co.za/index.php/sajgo/article/view/90
dc.description.versionPublisher's version
dc.format.extent8 pages
dc.identifier.citationBotha, M. H. et al. 2012. Preliminary investigation of a new serum marker for ovarian cancer. South African Journal of Gynaecological Oncology, 4(1):13-20.
dc.identifier.issn2220-105X (online)
dc.identifier.issn2074-2835 (print)
dc.identifier.urihttp://hdl.handle.net/10019.1/81869
dc.language.isoen
dc.publisherMedpharm Publications
dc.rights.holderSouth African Society of Gynaecologic Oncology
dc.subjectOvaries -- Canceren_ZA
dc.subjectGenerative organs, Female -- Canceren_ZA
dc.titlePreliminary investigation of a new serum marker for ovarian canceren_ZA
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
botha_preliminary_2012.pdf
Size:
346.05 KB
Format:
Adobe Portable Document Format
Description:
Download article
Download
Collections
Research Articles (Obstetrics and Gynaecology)